scholarly journals Reduced Intensity Conditioning Yields Superior Overall Survival Rates Compared to Myeloablative Regimens for Allogeneic HCT in Chronic Lymphocytic Leukemia: A Side-By-Side Systematic Review/Meta-Analysis

2017 ◽  
Vol 23 (3) ◽  
pp. S269 ◽  
Author(s):  
Jessica El-Asmar ◽  
Tea Reljic ◽  
Ambuj Kumar ◽  
Mohamed A. Kharfan-Dabaja
Keyword(s):  
Systematic Review ◽  
Overall Survival ◽  
Chronic Lymphocytic Leukemia ◽  
Meta Analysis ◽  
Survival Rates ◽  
Lymphocytic Leukemia ◽  
Reduced Intensity Conditioning ◽  
Allogeneic Hct ◽  
Reduced Intensity ◽  
Overall Survival Rates

A breakthrough in the treatment of chronic lymphocytic leukemia

2020 ◽  
pp. 39-42
Author(s):  
Yuliya Prozherina ◽  
◽  
Irina Shirokova ◽  
Keyword(s):  
Overall Survival ◽  
Chronic Lymphocytic Leukemia ◽  
B Cell ◽  
Survival Rates ◽  
Cell Receptor ◽  
Common Type ◽  
B Cell Receptor ◽  
Lymphocytic Leukemia ◽  
Receptor Signalling ◽  
Overall Survival Rates

Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in adults. Its prevalence is expected to increase alongside rising overall survival rates in patients with CLL achieved due to advances in therapy [1]. B-cell receptor signalling through Bruton’s tyrosine kinase (BTK) is one of the main pathways for the development of CLL. Acalabrutinib, the second-generation VTK inhibitor, has been made available recently to Russian patients, which presence in the market can improve the prognosis for such patients.

FA03.02: IS SURGERY STILL NECESSARY IN RESECTABLE OESOPHAGEAL CANCER? META-ANALYSES OF DEFINITIVE CHEMORADIOTHERAPY VERSUS TRIMODALITY THERAPY

2018 ◽  
Vol 31 (Supplement_1) ◽  
pp. 6-6
Author(s):  
Daan Voeten ◽  
Chantal Den Bakker ◽  
Donald Van Der Peet
Keyword(s):  
Systematic Review ◽  
Overall Survival ◽  
Survival Rates ◽  
Oesophageal Carcinoma ◽  
Risk Of Bias ◽  
Survival Advantage ◽  
Definitive Chemoradiotherapy ◽  
Trimodality Therapy ◽  
Meta Analyses ◽  
Overall Survival Rates

Abstract Background Standard therapy for resectable oesophageal carcinoma is trimodality therapy (TMT) consisting of neoadjuvant chemoradiotherapy and oesophagectomy. Evidence of survival advantage of TMT over organ preserving definitive chemoradiotherapy (dCRT) is inconclusive. The aim of this study is to compare survival between TMT and dCRT. Methods A systematic review and meta-analyses were conducted. Randomised controlled trials and observational studies on primary resectable, curatively treated, oesophageal carcinoma patients above 18 years were included. Three online databases were searched for studies comparing TMT with dCRT. Primary outcomes were two-, three- and five-year overall survival rates. Risk of bias was assessed using the Cochrane risk of bias tools for RCTs and cohort studies. Results Thirty-two studies described in 35 articles were included in this systematic review, thirty-three were included in the meta-analyses. Two-, three- and five-year overall survival was significantly lower in dCRT compared to TMT, with relative risks (RR) of 0.69 (95%CI, 0.57–0.83), 0.76 (95%CI, 0.63–0.92), and 0.57 (95%CI, 0.47–0.71) respectively. However, when only analysing studies with equal patient groups at baseline no differences for two-, three- and five-year overall survival were found with RRs of 0.83 (95%CI, 0.62–1.10), 0.81 (95%CI 0.57–1.14), 0.63 (95%CI, 0.36–1.12). The forest plot for three-year overall survival is presented in figure 1. Figure 1. 3 year overall survival rates Conclusion Despite limitations of the available evidence these meta-analyses suggest there is no survival advantage for TMT over dCRT, assuming comparable groups at baseline. Selection of surgical candidates in oesophageal carcinoma should be part of personalised and tailored care. Disclosure All authors have declared no conflicts of interest.

Sign in / Sign up

Export Citation Format

Share Document